Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

CEO

ISIN

IL0011429839

Listings

0 Comments

Share your thoughts

FAQ

What is Entera Bio stock price today?▼

The current price of ENTX.BOATS is $1.03 USD — it has decreased by -12.71% in the past 24 hours. Watch Entera Bio stock price performance more closely on the chart.

What is Entera Bio stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Entera Bio stocks are traded under the ticker ENTX.BOATS.

What is Entera Bio market cap?▼

Today Entera Bio has the market capitalization of 47.23M

When is the next Entera Bio earnings date?▼

Entera Bio is going to release the next earnings report on May 08, 2026.

What were Entera Bio earnings last quarter?▼

ENTX.BOATS earnings for the last quarter are -0.07 USD per share, whereas the estimation was -0.09 USD resulting in a +22.22% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Entera Bio revenue for the last year?▼

Entera Bio revenue for the last year amounts to 362,000 USD.

What is Entera Bio net income for the last year?▼

ENTX.BOATS net income for the last year is -19.08M USD.

When did Entera Bio complete a stock split?▼

Entera Bio has not had any recent stock splits.